HER2 assessment by silver in situ hybridization: where are we now?

References

• Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda) 2010;25:85-101
   PubMed Web of Science ®Google Scholar
• Emde A, Kostler WJ, Yarden Y. Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol 2012;84(Suppl 1):e49-57
   PubMedGoogle Scholar
• Dedic Plavetic N, Kulic A, Vrbanec D. Role of HER2 signaling pathway in breast cancer: biology, detection and therapeutical implications. Period Biolog 2012;114:505-10
   Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37
   PubMed Web of Science ®Google Scholar
• Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-23
   PubMed Web of Science ®Google Scholar
• Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12–21.32. Genomics 1989;4:362-6
   PubMed Web of Science ®Google Scholar
• Odicino FE, Bignotti E, Rossi E, et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer 2008;18:14-21
   PubMed Web of Science ®Google Scholar
• Miyahara N, Shoda J, Ishige K, et al. MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. Eur J Cancer 2008;44:1048-56
   PubMedGoogle Scholar
• Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009;100:487-93
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904
   PubMed Web of Science ®Google Scholar
• Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991;49:650-5
   PubMed Web of Science ®Google Scholar
• Schuell B, Gruenberger T, Scheithauer W, et al. HER 2/neu protein expression in colorectal cancer. BMC Cancer 2006;6:123
   PubMed Web of Science ®Google Scholar
• Eltze E, Wülfing C, Von Struensee D, et al. Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol 2005;26:1525-31
   PubMed Web of Science ®Google Scholar
• McKenzie SJ, DeSombre KA, Bast BS, et al. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 1993;71:3942-6
   PubMed Web of Science ®Google Scholar
• Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-85
   PubMed Web of Science ®Google Scholar
• Hirashima N, Takahashi W, Yoshii S, et al. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 2001;14:556-62
   PubMedGoogle Scholar
• Mitra AB, Murty VV, Pratap M, et al. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994;54:637-9
   PubMed Web of Science ®Google Scholar
• Beckhardt RN, Kiyokawa N, Xi L, et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995;121:1265-70
   PubMed Web of Science ®Google Scholar
• Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-87
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Bilous M, Dowsett M, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol 2009;132:539-48
   PubMed Web of Science ®Google Scholar
• Thang VH, Tani E, Van TT, et al. HER2 status in operable breast cancers from Vietnamese women: analysis by immunohistochemistry (IHC) and automated silver enhanced in situ hybridization (SISH). Acta Oncol 2011;50:360-6
   PubMed Web of Science ®Google Scholar
• Liu E, Thor A, He M, et al. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992;7:1027-32
   PubMed Web of Science ®Google Scholar
• Park K, Han S, Kim HJ, et al. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006;48:702-7
   PubMed Web of Science ®Google Scholar
• Carlsson J, Nordgren H, Sjostrom J, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344-8
   PubMed Web of Science ®Google Scholar
• Paik S, Park C. HER-2 and choice of adjuvant chemotherapy in breast cancer. Semin Oncol 2001;28:332-5
   PubMedGoogle Scholar
• Villman K, Sjostrom J, Heikkila R, et al. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol 2006;45:590-6
   PubMed Web of Science ®Google Scholar
• Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of Topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23:7483-90
   PubMed Web of Science ®Google Scholar
• Dekker TJ, Borg ST, Hooijer GK, et al. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res 2012;14:R93
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45
   PubMed Web of Science ®Google Scholar
• Hanna WM, Ruschoff J, Bilous M, et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 2014;27:4-18
   PubMedGoogle Scholar
• Zhou Z, Hick DG. HER2 amplification or overexpression in upper GI tract and breast cancer with clinical diagnosis and treatment ( chapter In: Siregar Y, editors. Oncogene and cancer – from bench to clinic. Intech, Croatia; 2013
   Google Scholar
• Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)- overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95
   PubMed Web of Science ®Google Scholar
• Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-80
   PubMedGoogle Scholar
• Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
   PubMed Web of Science ®Google Scholar
• Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28:13-19
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer. N Engl J Med 2005;353:1659-72
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. N Engl J Med 2005;353:1673-84
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36
   PubMed Web of Science ®Google Scholar
• Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. Oncologist 2011;16:800-10
   PubMed Web of Science ®Google Scholar
• Banerjee S, Smith IE. Management of small HER2- positive breast cancers. Lancet Oncol 2010;11:1193-9
   PubMed Web of Science ®Google Scholar
• Jackisch C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist 2006;11(Suppl 1):34-41
   PubMed Web of Science ®Google Scholar
• Loi S, de Azambuja E, Pugliano L, et al. HER2- overexpressing breast cancer: time for the cure with less chemotherapy? Curr Opin Oncol 2011;23:547-58
   PubMedGoogle Scholar
• Tagliabue E, Campiglio M, Pupa SM, et al. The HER2 World: better Treatment Selection for Better Outcome. J Natl Cancer Inst Monogr 2011;2011:82-5
   PubMedGoogle Scholar
• Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40
   PubMed Web of Science ®Google Scholar
• Gravalos C, Gomez-Martin C, Rivera F, et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 2011;13:179-84
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
   PubMed Web of Science ®Google Scholar
• Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011;17:2055-64
   PubMed Web of Science ®Google Scholar
• Somlo G, Martel CL, Lau SK, et al. A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Res Treat 2012;131:899-906
   PubMed Web of Science ®Google Scholar
• Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 2012;25:938-48
   PubMed Web of Science ®Google Scholar
• Sakai K, Mori S, Kawamoto T. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986;77:1047-52
   PubMed Web of Science ®Google Scholar
• Houldsworth J, Cordon-Cardo C, Ladanyi M, et al. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990;50:6417-22
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
   PubMed Web of Science ®Google Scholar
• Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33
   PubMed Web of Science ®Google Scholar
• Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-8
   PubMed Web of Science ®Google Scholar
• Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-9
   PubMed Web of Science ®Google Scholar
• Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010;28:1547-53
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012;23:2656-62
   PubMed Web of Science ®Google Scholar
• Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic valued conclusions from 924 cases of two independent series. Cell Oncol 2010;32:57-65
   PubMed Web of Science ®Google Scholar
• Gurel S, Dolar E, Yerci O, et al. The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer. J Int Med Res 1999;27:74-8
   PubMedGoogle Scholar
• Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-9
   PubMed Web of Science ®Google Scholar
• Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010;63:839-42
   PubMed Web of Science ®Google Scholar
• Shah MA, Janjigian YY, Pauligk C. Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: a U.S. and European international collaborative analysis. J Clin Oncol 2011;29(Suppl):abstract 4014
   Google Scholar
• Yoon HH, Shi Q, Sukov WR. HER2 expression/amplification: frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). J Clin Oncol 2011;29(Suppl):abstract 4012
   Google Scholar
• Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe 2010;31:208-17
   PubMedGoogle Scholar
• Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307
   PubMed Web of Science ®Google Scholar
• Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25:637-50
   PubMed Web of Science ®Google Scholar
• de Mello RA, Marques AM, Araújo A. HER2 therapies and gastric cancer: A step forward. World J Gastroenterol 2013;19:6165-9
   PubMed Web of Science ®Google Scholar
• Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 2012;104:159-62
   PubMedGoogle Scholar
• Coudert BP, Arnould L, Moreau L, et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2006;17:409-14
   PubMed Web of Science ®Google Scholar
• Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 2009;27:2962-9
   PubMedGoogle Scholar
• NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 3.2014, BINV-2
   Google Scholar
• Dowsett M, Hanna WM, Kockx M, et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol 2007;20:584-91
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. american society of clinical oncology/college of american pathologists clinical practice guideline update. Arch Pathol Lab Med 2014;138:241-56
   PubMed Web of Science ®Google Scholar
• Lacroix-Triki M, Mathoulin-Pelissier S, Ghnassia JP, et al. High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study. Eur J Cancer 2006;42:2946-53
   PubMedGoogle Scholar
• Penault-Llorca F, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 1994;173:65-75
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Jacquemier J, Le DV, Voigt JJ. Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for Evaluation of Prognostic Factors in Immunohistochemistry in Breast Cancer (GEFPICS). Ann Pathol 1999;19:280-2
   PubMedGoogle Scholar
• Penault-Llorca F, Vincent-Salomon A, Bellocq JP, et al. Update of the GEFPICS’ recommendations for HER2 status determination in breast cancers in France. Ann Pathol 2010;30:357-73
   PubMedGoogle Scholar
• Vincent-Salomon A, MacGrogan G, Couturier J, et al. Re: HER2 testing in the real world. J Natl Cancer Inst 2003;95:628-9
   PubMedGoogle Scholar
• Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 2003;42:337-47
   PubMed Web of Science ®Google Scholar
• Wells CA, Sloane JP, Coleman D, et al. Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union–an inter-laboratory study. Virchows Arch 2004;445:119-28
   PubMed Web of Science ®Google Scholar
• Kim MA, Jung JE, Lee HE, et al. In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry. Hum Pathol 2013;44:487-94
   PubMed Web of Science ®Google Scholar
• Paik S, Bryant J, Tan-Chiu E, et al. Real- world performance of HER2 testing: national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 2002;94:852-4
   PubMed Web of Science ®Google Scholar
• Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-7
   PubMedGoogle Scholar
• Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68
   PubMed Web of Science ®Google Scholar
• Park K, Han S, Kim JY, et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer. J Breast Cancer 2011;14:276-82
   PubMedGoogle Scholar
• Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-33
   PubMed Web of Science ®Google Scholar
• Babic A, Loftin IR, Stanislaw S, et al. The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. Methods 2010;52:287-300
   PubMedGoogle Scholar
• Burandt E, Sauter G. HER2 ASCO guidelines. The answer to everything? Pathologe 2010;31(Suppl 2):285-91
   PubMedGoogle Scholar
• Moatamed NA, Nanjangud G, Pucci R, et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol 2011;136:754-61
   PubMedGoogle Scholar
• Jacquemier J, Spyratos F, Esterni B, et al. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer 2013;13:351
   PubMed Web of Science ®Google Scholar
• Tse CH, Hwang HC, Goldstein LC, et al. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol 2011;29:4168-74
   PubMed Web of Science ®Google Scholar
• Schiavon BN, Jasani B, de Brot L, et al. Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting. Influence of poor tissue preservation. Am J Surg Pathol 2012;36:1489-96
   PubMedGoogle Scholar
• Garcia-Garcia E, Gomez-Martin C, Angulo B, et al. Hybridization for HER2 testing in gastric carcinoma: a comparison of fluorescence in situ hybridization with a novel fully automated dual-color silver in situ hybridization. Histopathology 2011;59:8-17
   PubMedGoogle Scholar
• Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 2005;36:250-61
   PubMed Web of Science ®Google Scholar
• Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol 2007;16:207-10
   PubMedGoogle Scholar
• Hauser-Kronberger C, Dandachi N. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol 2004;35:647-53
   PubMedGoogle Scholar
• Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007;451:19-25
   PubMed Web of Science ®Google Scholar
• Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004;22:854-63
   PubMed Web of Science ®Google Scholar
• Francis GD, Jones MA, Beadle GF, Stein SR. Bright- field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol 2009;18:88-95
   PubMed Web of Science ®Google Scholar
• Papouchado BG, Myles J, Lloyd RV, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 2010;34:767-76
   PubMedGoogle Scholar
• Ying JM, Guo L, Liu XY, et al. Automated silver-enhanced in situ hybridization detection assay for human epidermal growth factor receptor 2 gene status determination in breast cancer. Zhonghua Yi Xue Za Zhi 2010;90:1674-7
   PubMedGoogle Scholar
• Arnould L, Roger P, Macgrogan G, et al. Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH). Mod Pathol 2012;25:675-82
   PubMedGoogle Scholar
• Isola J, Tanner M, Forsyth A, et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004;10:4793-8
   PubMed Web of Science ®Google Scholar
• Laakso M, Tanner M, Isola J. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol 2006;210:3-9
   PubMed Web of Science ®Google Scholar
• Arnould L, Denoux Y, MacGrogan G, et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003;88:1587-91
   PubMed Web of Science ®Google Scholar
• Carbone A, Botti G, Gloghini A, et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn 2008;10:527-36
   PubMed Web of Science ®Google Scholar
• Bilous M, Morey A, Armes J, et al. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. Pathology 2006;38:120-4
   PubMed Web of Science ®Google Scholar
• Farshid G, Armes JE, Bell R, et al. Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice. Diagn Mol Pathol 2010;19:187-93
   PubMedGoogle Scholar
• Tubbs R, Pettay J, Skacel M, et al. Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of HER- 2/neu gene amplification. Am J Pathol 2002;160:1589-95
   PubMed Web of Science ®Google Scholar
• Downs-Kelly E, Pettay J, Hicks D, et al. Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol 2005;29:1505-11
   PubMedGoogle Scholar
• Bieche I, Olivi M, Champeme MH, et al. Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer 1998;78:661-6
   PubMedGoogle Scholar
• Suo Z, Daehli KU, Lindboe CF, et al. Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients. Int J Surg Pathol 2004;12:311-18
   PubMedGoogle Scholar
• Bergqvist J, Ohd JF, Smeds J, et al. Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol 2007;18:845-50
   PubMed Web of Science ®Google Scholar
• Susini T, Bussani C, Marini G, et al. Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens. Gynecol Oncol 2010;116:234-9
   PubMedGoogle Scholar
• Kulka J, Tokes AM, Kaposi-Novak P, et al. Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results. Pathol Oncol Res 2006;12:197-204
   PubMedGoogle Scholar
• Ntoulia M, Kaklamanis L, Valavanis C, et al. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. Clin Biochem 2006;39:942-6
   PubMedGoogle Scholar
• Monego G, Arena V, Maggiano N, et al. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values. Scand J Clin Lab Invest 2007;67:402-12
   PubMed Web of Science ®Google Scholar
• Lamy PJ, Nanni I, Fina F, et al. Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer. Int J Biol Markers 2006;21:20-9
   PubMedGoogle Scholar
• Press MF, Finn RS, Cameron D, et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 2008;14:7861-70
   PubMed Web of Science ®Google Scholar
• Vinatzer U, Dampier B, Streubel B, et al. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res 2005;11:8348-57
   PubMedGoogle Scholar
• Barberis M, Pellegrini C, Cannone M, et al. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am J Clin Pathol 2008;129:563-70
   PubMedGoogle Scholar
• Tvrdik D, Stanek L, Skalova H, et al. Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer. Mol Med Rep 2012;6:439-43
   PubMedGoogle Scholar
• Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, et al. Real- time reverse transcription-PCR and fluorescence in situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology 2005;46:431-41
   PubMedGoogle Scholar
• Bustin SA, Nolan T. Pitfalls of quantitative real-time reverse- transcription polymerase chain reaction. J Biomol Tech 2004;15:155-66
   PubMedGoogle Scholar
• Gruver AM, Peerwani Z, Tubbs RR. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol 2010;63:210-19
   PubMedGoogle Scholar
• Powell RD, Pettay JD, Powell WC, et al. Metallographic in situ hybridization. Hum Pathol 2007;38:1145-59
   PubMedGoogle Scholar
• Kang J, Kwon GY, Lee YH, Gong G. Comparison of silver-enhanced in situ hybridization and fluorescence in situ hybridization for HER2 gene status in breast carcinomas. J Breast Cancer 2009;12:235-40
   Google Scholar
• Kim TJ, Kim TE, Jung ES, et al. The comparison of automated silver in situ hybridization and fluorescence in situ hybridization for evaluating HER2 gene amplification in breast carcinoma. J Breast Cancer 2009;12:295-301
   Google Scholar
• Unal B, Karaveli FS, Pestereli HE, Erdogan G. Determination of HER2 Gene Amplification in Breast Cancer using Dual-color Silver Enhanced in situ Hybridization (dc- SISH) and Comparison with Fluorescence ISH (FISH). Asian Pac J Cancer Prev 2013;14:6131-4
   PubMedGoogle Scholar
• Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al. Development of automated bright field double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN17) for breast carcinomas and an assay performance comparison to manual dual colour HER2 fluorescence in situ hybridization (FISH). Diagn Pathol 2008;3:41
   PubMed Web of Science ®Google Scholar
• Koh YW, Lee HJ, Lee JW, et al. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod Pathol 2011;24:794-800
   PubMed Web of Science ®Google Scholar
• Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol 2009;18:96-102
   PubMedGoogle Scholar
• Cell Markers and Cytogenetics Committees College of American Pathologists. Clinical laboratory assays for HER- 2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 2002;126:803-8
   PubMedGoogle Scholar
• Fritzsche FR, Bode PK, Moch H, et al. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH). Am J Surg Pathol 2010;34:1180-5
   PubMedGoogle Scholar
• Bartlett JM, Campbell FM, Ibrahim M, et al. Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH. Am J Clin Pathol 2009;132:514-20
   PubMedGoogle Scholar
• Sung WJ, Park SJ, Gu MJ, Bae YK. Automated silver-enhanced in situ hybridization for evaluation of HER2 gene status in breast carcinoma: comparison with fluorescence in situ hybridization and immunohistochemistry. Korean J Pathol 2010;44:28-34
   Google Scholar
• Fassan M, Mastracci L, Grillo F, et al. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 2012;61:769-76
   PubMed Web of Science ®Google Scholar
• Lee Y, Ryu Y, Jeong H, et al. Effectiveness of silver- enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study. Arch Med Res 2012;43:139-44
   PubMedGoogle Scholar
• Shousha S, Peston D, Amo-Takyi B, et al. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 2009;54:248-53
   PubMedGoogle Scholar
• Arnould L, Arveux P, Couturier J, et al. Pathologic complete response to Trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007;13:6404-9
   PubMed Web of Science ®Google Scholar
• Tubbs R, Pettay J, Hicks D, et al. Novel bright field molecular morphology methods for detection of HER2 gene amplification. J Mol Histol 2004;35:589-94
   PubMed Web of Science ®Google Scholar
• Kosa C, Kardos L, Kovacs J, Szollosi Z. Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment. Pathol Res Pract 2013;209:147-50
   PubMedGoogle Scholar
• Bilous M, Ades C, Armes J, et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 2003;12:92-8
   PubMed Web of Science ®Google Scholar
• Bae YK, Gong G, Kang J, et al. HER2 status by standardized immunohistochemistry and silver-enhanced in situ hybridization in korean breast cancer. J Breast Cancer 2012;15:381-7
   PubMedGoogle Scholar
• Rossi E, Ubiali A, Cadei M, et al. Her-2/neu in breast cancer. A comparative study between histology, immunohistochemistry, and molecular technique (FISH). Appl Immunohistochem Mol Morphol 2006;14:127-31
   PubMedGoogle Scholar
• Capizzi E, Gruppioni E, Grigioni AD, et al. Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry. Diagn Mol Pathol 2008;17:220-6
   PubMedGoogle Scholar
• Siñczak-Kuta A, Tomaszewska R, Rudnicka-Sosin L, et al. Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. comparison of in situ hybridization methods. Pol J Pathol 2007;58:41-50
   PubMedGoogle Scholar
• Jang JS, Jang EJ, Park J-Y. HER2 expression in breast cancer: comparisons of fluorescence in situ hybridization and silver in situ hybridization, and immunohistochemical staining using monoclonal antibody and polyclonal antibody. Basic and Applied Pathology 2010;3:115-20
   Google Scholar
• Rhodes A, Sarson J, Assam EE, et al. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am J Clin Pathol 2010;134:621-32
   PubMed Web of Science ®Google Scholar
• Park YS, Hwang HS, Park HJ, et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 2012;43:413-22
   PubMed Web of Science ®Google Scholar
• Long XY, Bu H, Wei B, et al. [Dual-color silver-enhanced in-situ hybridization and fluorescence in-situ hybridization for determination of HER2 gene status in gastric carcinoma]. Zhonghua Bing Li Xue Za Zhi 2011;40:300-3
   PubMedGoogle Scholar
• Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011;58:383-94
   PubMed Web of Science ®Google Scholar
• Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 2008;26:4869-74
   PubMed Web of Science ®Google Scholar
• Hyun CL, Lee HE, Kim KS, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 2008;61:317-21
   PubMedGoogle Scholar
• Torrisi R, Rotmensz N, Bagnardi V, et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 2007;43:2339-44
   PubMed Web of Science ®Google Scholar
• Shah SS, Wang Y, Tull J, Zhang S. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma. Diagn Mol Pathol 2009;18:30-3
   PubMedGoogle Scholar
• Reinholz MM, Bruzek AK, Visscher DW, et al. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 2009;10:267-77
   PubMed Web of Science ®Google Scholar
• Marchiò C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009;219:16-24
   PubMed Web of Science ®Google Scholar
• Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 2009;22:1169-75
   PubMed Web of Science ®Google Scholar
• Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 2010;120:1-7
   PubMedGoogle Scholar
• Murthy SS, Sandhya DG, Ahmed F, et al. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center. Indian J Pathol Microbiol 2011;54:532-8
   PubMedGoogle Scholar
• Kim A, Shin HC, Bae YK, et al. Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status. J Breast Cancer 2012;15:24-33
   PubMedGoogle Scholar
• Perez EA, Reinholz MM, Hillman DW, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010;28:4307-15
   PubMed Web of Science ®Google Scholar
• Downey L, Livingston RB, Koehler M, et al. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res 2010;16:1281-8
   PubMedGoogle Scholar
• Hofmann M, Stoss O, Gaiser T, et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 2008;61:89-94
   PubMed Web of Science ®Google Scholar
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline update. Available from: www.asco.org/guidelines/her2 [Last accessed on 30 May 2014]
   Google Scholar
• Viale G. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J Pathol 2009.219:1-2
   Google Scholar
• Hanna W, Nofech-Mozes S, Kahn HJ. Intratumoral heterogeneity of HER2/neu in breast cancer—a rare event. Breast J 2007;13:122-9
   PubMedGoogle Scholar
• Wu JM, Halushka MK, Argani P. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol 2010;41:914-17
   PubMed Web of Science ®Google Scholar
• Sekido Y, Umemura S, Takekoshi S, et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol 2003;22:1225-32
   PubMedGoogle Scholar
• Lewis JT, Ketterling RP, Halling KC, et al. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 2005;124:273-81
   PubMedGoogle Scholar
• Nassar A, Radhakrishnan A, Cabrero IA, et al. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol 2010;18:433-41
   PubMedGoogle Scholar
• Bartlett AI, Starcyznski J, Robson T, et al. Is 5-50% of amplified cells a suitable cut-off to define heterogeneous amplification of the HER2 oncogene? Poster presentation at the 33rd Annual San Antonio Breast Cancer Symposium; San Antonio, TX, USA; 8-12 December 2010
   Google Scholar
• Fujii H, Marsh C, Cairns P, et al. Genetic divergence in the clonal evolution of breast cancer. Cancer Res 1996;56:1493-7
   PubMedGoogle Scholar
• Bartlett AI, Starcyznski J, Robson T, et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 2011;136:266-74
   PubMed Web of Science ®Google Scholar
• Shah S, Chen B. Testing for HER2 in breast cancer: a continuing evolution. Pathol Res Int 2010;2011:903202
   PubMedGoogle Scholar
• Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009;133:611-12
   PubMed Web of Science ®Google Scholar
• Chang MC, Malowany JI, Mazurkiewicz J, Wood M. ‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases. Mod Pathol 2012;25:683-8
   PubMed Web of Science ®Google Scholar
• Bilous M, Osamura RY, Ruschoff J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2010;41:304-5
   PubMedGoogle Scholar
• Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011;104:1372-6
   PubMed Web of Science ®Google Scholar
• Kimura M, Tsuda H, Morita D, et al. Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. Jpn J Clin Oncol 2005;35:324-31
   PubMedGoogle Scholar
• Langer R, Rauser S, Feith M, et al. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod Pathol 2011;24:908-16
   PubMed Web of Science ®Google Scholar
• Abraham SC, Park SJ, Lee JH, et al. Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes. Mod Pathol 2003;16:786-95
   PubMedGoogle Scholar
• Kim MA, Lee HJ, Yang HK, et al. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011;59:822-31
   PubMed Web of Science ®Google Scholar
• Lee S, de Boer WB, Fermoyle S, et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 2011;59:832-40
   PubMed Web of Science ®Google Scholar
• Tafe LJ, Janjigian YY, Zaidinski M, et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 2011;135:1460-5
   PubMed Web of Science ®Google Scholar
• Yan B, Yau EX, Choo SN, et al. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol 2011;64:880-3
   PubMedGoogle Scholar
• Warneke VS, Behrens H-M, Boger C, et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 2013;24:725-33
   PubMed Web of Science ®Google Scholar
• Taboada S, Whitney-Miller CL. Updates in HER2 testing in gastric cancer. J Gastroint Dig Syst 2013;3:2
   Google Scholar
• Lee HE, Park KU, Yoo SB, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 2013;49:1448-57
   PubMed Web of Science ®Google Scholar